Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4694229 | 0.81 | ESR1 (0.58) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL18386353 | 0.81 | CCR1 (0.38) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL5879335 | 0.81 | ESR1 (0.37) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL988872 | 0.81 | TRPA1 (0.42) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL3657890 | 0.69 | ESR1 (0.37) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL5879102 | 0.68 | HRH1 (0.39) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL17109517 | 0.64 | ESR2 (0.38) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL3795410 | 0.64 | ESR1 (0.33) | ESR1ESR2MEN1ALDH1A1CYP1A2 | |
| SCHEMBL29664551 | 0.64 | LOX (0.39) | ALDH1A1CYP3A4KMT2A | |
| SCHEMBL1759825 | 0.63 | ESR1 (0.33) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034056-B2 | Aryl and biaryl compounds having MCH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1370520-A1 | ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | SCHERING CORPORATION | 2003-05-15 | — | — | US | disclosed |
| WO-2002076929-A1 | ARYL AND BIARYL COMPOUNDS HAVING MCH MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | MCHR1, MCHR2, MC3R | ESR1 1011/4885ESR2 532/4885MEN1 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.